<DOC>
	<DOCNO>NCT00009867</DOCNO>
	<brief_summary>Phase II trial study effectiveness arsenic trioxide treat patient recurrent cancer bladder urinary tract . Arsenic trioxide may kill tumor cell become resistant standard chemotherapy regimen .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Urothelial Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine efficacy arsenic trioxide patient measurable urothelial carcinoma bladder , urethra , ureter , renal pelvis . II . To determine toxicity arsenic trioxide administer patient urothelial cancer . OUTLINE : Patients receive arsenic trioxide IV 1 hour day 1-5 . Treatment repeat every 28 day minimum 2 course absence disease progression unacceptable toxicity . Patients achieve complete response receive 2 additional course . Patients follow every 2 month 1 year registration every 6 month 1 year disease progression relapse .</detailed_description>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Diagnosis transitional cell carcinoma bladder , urethra , ureter renal pelvis ; histologic documentation metastatic/recurrent disease require ; clinical staging , pathological staging , required Patients must relapse fail achieve complete partial response one chemotherapy regimen , must include one follow chemotherapy agent : cisplatin , carboplatin paclitaxel , gemcitabine &gt; = 4 week since prior RT chemotherapy Patients must measurable disease CTC ( ECOG ) Performance Status = &lt; 1 No evidence NYHA functional class III IV heart disease Baseline EKG QTc &lt; 500 m Nonpregnant nursing , chemotherapy think present substantial risk fetus/infant ; men woman reproductive potential may participate unless agree use effective contraceptive method study Granulocytes &gt; 1500/ml Platelet count &gt; 100,000/ml Bilirubin = &lt; Upper limit normal ( ULN ) Serum Creatinine &lt; 2.0 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>